Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patients

被引：24

作者：

Nakamura, Yasuhiro ^{[1
,27
]}

Namikawa, Kenjiro ^{[2
]}

Kiniwa, Yukiko ^{[3
]}

Kato, Hiroshi ^{[4
]}

Yamasaki, Osamu ^{[5
]}

Yoshikawa, Shusuke ^{[6
]}

Maekawa, Takeo ^{[7
]}

Matsushita, Shigeto ^{[8
]}

Takenouchi, Tatsuya ^{[9
]}

Inozume, Takashi ^{[10
]}

Nakai, Yasuo ^{[11
]}

Fukushima, Satoshi ^{[12
]}

Saito, Shintaro ^{[13
]}

Otsuka, Atsushi ^{[14
,15
]}

Fujimoto, Noriki ^{[16
]}

Isei, Taiki ^{[17
]}

Baba, Natsuki ^{[18
]}

Matsuya, Taisuke ^{[19
]}

Tanaka, Ryo ^{[20
]}

Kaneko, Takahide ^{[21
]}

Onishi, Masazumi ^{[22
]}

Kuwatsuka, Yutaka ^{[23
]}

Nagase, Kotaro ^{[24
]}

Onuma, Takehiro ^{[25
]}

Nomura, Motoo ^{[26
]}

Umeda, Yoshiyasu ^{[1
,20
]}

Yamazaki, Naoya ^{[2
]}

机构：

[1] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, Saitama, Japan

[2] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan

[3] Shinshu Univ, Dept Dermatol, Matsumoto, Japan

[4] Nagoya City Univ, Dept Geriatr & Environm Dermatol, Grad Sch Med Sci, Nagoya, Japan

[5] Okayama Univ, Dept Dermatol, Dent & Pharmaceut Sci, Grad Sch Med, Okayama, Japan

[6] Shizuoka Canc Ctr, Dermatol Div, Shizuoka, Japan

[7] Jichi Med Univ, Dept Dermatol, Tochigi, Japan

[8] Natl Hosp Org, Dept Dermato Oncol Dermatol, Kagoshima Med Ctr, Kagoshima, Japan

[9] Niigata Canc Ctr Hosp, Dept Dermatol, Niigata, Japan

[10] Chiba Univ, Dept Dermatol, Chiba, Japan

[11] Mie Univ, Dept Dermatol, Mie, Japan

[12] Kumamoto Univ, Fac Life Sci, Dept Dermatol & Plast Surg, Kumamoto, Japan

[13] Gunma Univ, Dept Dermatol, Grad Sch Med, Maebashi, Japan

[14] Kyoto Univ, Dept Dermatol, Kyoto, Japan

[15] Kindai Univ Hosp, Dept Dermatol, Osaka, Japan

[16] Shiga Univ Med Sci, Dept Dermatol, Otsu, Japan

[17] Osaka Int Canc Inst, Dept Dermatol Oncol, Osaka, Japan

[18] Univ Fukui, Dept Dermatol, Fukui, Japan

[19] Asahikawa Med Univ, Dept Dermatol, Asahikawa, Japan

[20] Kawasaki Med Sch, Dept Dermatol, Kurashiki, Japan

[21] Juntendo Univ, Dept Dermatol, Urayasu Hosp, Chiba, Japan

[22] Iwate Med Univ, Dept Dermatol, Iwate, Japan

[23] Nagasaki Univ, Dept Dermatol, Nagasaki, Japan

[24] Saga Univ, Fac Med, Dept Internal Med, Div Dermatol, Saga, Japan

[25] Univ Yamanashi, Dept Dermatol, Yamanashi, Japan

[26] Kyoto Univ, Dept Clin Oncol, Kyoto, Japan

[27] Saitama Med Univ, Dept Skin Oncol Dermatol, Int Med Ctr, 1397-1 Yamane, Saitama 3501298, Japan

来源：

EUROPEAN JOURNAL OF CANCER | 2022年 / 176卷

关键词：

CTLA-4; antigen; Immunotherapy; Ipilimumab; Melanoma; Nivolumab; Pembrolizumab; Programmed cell death 1 receptor; Retrospective studies; Japan; SINGLE-ARM; OPEN-LABEL; PD-1; BLOCKADE; PHASE-II; MUCOSAL; IPILIMUMAB; INHIBITORS; NIVOLUMAB; MUTATION; SAFETY;

D O I：

10.1016/j.ejca.2022.08.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Although anti-PD-1 antibody monotherapy (PD-1) is commonly used to treat advanced acral melanoma (AM), its efficacy is limited. Further, data on the efficacy of PD-1 plus anti-CTLA-4 antibody (PD-1+CTLA-4) for the treatment of AM are limited. Therefore, we compared the efficacy of PD-1+CTLA-4 and PD-1 in the treatment of Japanese patients with advanced AM. Methods: This retrospective study evaluated patients with advanced AM who were treated with PD-1 or PD-1+CTLA-4 as first-line immunotherapy in 24 Japanese institutions between 2014 and 2020. Treatment efficacy focussing on the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) was compared between the two groups. Results: In total, 254 patients (palm and sole melanoma [PSM], n = 180; nail apparatus melanoma [NAM], n = 74) were included. Among the patients with PSM, the ORR (19% vs. 31%; P = 0.44), PFS (5.9 vs. 3.2 months; P = 0.74), and OS (23.1 vs. not reached; P = 0.55) did not differ significantly between the PD-1 and PD-1+CTLA-4 groups. Among the patients with NAM, the ORR (61% vs. 10%; P < 0.001) was significantly higher and PFS was longer (6.4 vs. 3.8 months; P = 0.10) in the PD-1+CTLA-4 group than in the PD-1 group. Cox multivariate analysis demonstrated that PD-1+CTLA-4 is an independent predictor of a favourable PFS in patients with NAM (P = 0.002). Conclusions: The efficacy of PD-1+CTLA-4 is not superior to that of PD-1 for the treatment of advanced PSM. However, PD-1+CTLA-4 may be more efficacious than PD-1 for the treatment of advanced NAM. (C) 2022 Elsevier Ltd. All rights reserved.

引用

页码：78 / 87

页数：10

共 50 条

[31] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Celine Boutros
Ahmad Tarhini
Emilie Routier
Olivier Lambotte
Francois Leroy Ladurie
Franck Carbonnel
Hassane Izzeddine
Aurelien Marabelle
Stephane Champiat
Armandine Berdelou
Emilie Lanoy
Matthieu Texier
Cristina Libenciuc
Alexander M. M. Eggermont
Jean-Charles Soria
Christine Mateus
Caroline Robert
Nature Reviews Clinical Oncology, 2016, 13 : 473 - 486
[32] Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’
Keisuke Imafuku
Koji Yoshino
Kei Yamaguchi
Satoshi Tsuboi
Kuniaki Ohara
Hiroo Hata
British Journal of Cancer, 2017, 116 : e14 - e14
[33] Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
Imafuku, Keisuke
Yoshino, Koji
Yamaguchi, Kei
Tsuboi, Satoshi
Ohara, Kuniaki
Hata, Hiroo
BRITISH JOURNAL OF CANCER, 2017, 116 (08) : e14 - e14
[34] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy
Prithviraj, Prashanth
McArthur, Grant A.
Atkinson, Victoria
Parente, Phillip
Andrews, Miles Cameron
Parakh, Sagun
Cebon, Jonathan S.
Klein, Oliver
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[35] Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma
Campbell, Katie M.
Amouzgar, Meelad
Pfeiffer, Shannon M.
Howes, Timothy R.
Medina, Egmidio
Travers, Michael
Steiner, Gabriela
Weber, Jeffrey S.
Wolchok, Jedd D.
Larkin, James
Hodi, F. Stephen
Boffo, Silvia
Salvador, Lisa
Tenney, Daniel
Tang, Tracy
Thompson, Marshall A.
Spencer, Christine N.
Wells, Daniel K.
Ribas, Antoni
CANCER CELL, 2023, 41 (04) : 791 - +
[36] Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies
Kudo, Masatoshi
LIVER CANCER, 2019, 8 (06) : 413 - 426
[37] Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo
Das, Rituparna
Verma, Rakesh
Sznol, Mario
Boddupalli, Chandra Sekhar
Gettinger, Scott N.
Kluger, Harriet
Callahan, Margaret
Wolchok, Jedd D.
Halaban, Ruth
Dhodapkar, Madhav V.
Dhodapkar, Kavita M.
JOURNAL OF IMMUNOLOGY, 2015, 194 (03): : 950 - 959
[38] Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1
Robert, Caroline
Lebbe, Celeste
Lesimple, Thierry
Lundstrom, Eija
Nicolas, Valerie
Gavillet, Bruno
Crompton, Philippa
Baroudjian, Barouyr
Routier, Emilie
Lejeune, Ferdy J.
CLINICAL CANCER RESEARCH, 2023, 29 (05) : 858 - 865
[39] Defining melanoma patients unresponsive to single agent anti-PD-1 therapy but responsive to combination anti-PD-1+anti-CTLA-4 therapy
Edwards, Jarem J.
da Silva, Ines Pires
Ferguson, Angela
Johansson, Peter
Conway, Jordan
Attrill, Grace
Saw, Robyn P. M.
Thompson, John F.
Menzies, Alexander M.
Palendira, Umaimainthan
Long, Georgina, V
Scolyer, Richard A.
Wilmott, James S.
CANCER RESEARCH, 2020, 80 (16)
[40] Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
Bowyer, Samantha
Prithviraj, Prashanth
Lorigan, Paul
Larkin, James
McArthur, Grant
Atkinson, Victoria
Millward, Michael
Khou, Muoi
Diem, Stefan
Ramanujam, Sangeetha
Kong, Ben
Liniker, Elizabeth
Guminski, Alexander
Parente, Phillip
Andrews, Miles C.
Parakh, Sagun
Cebon, Jonathan
Long, Georgina V.
Carlino, Matteo S.
Klein, Oliver
BRITISH JOURNAL OF CANCER, 2017, 116 (08) : e15 - e15

← 1 2 3 4 5 →